Elanco

Elanco is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. Founded in 1954, Elanco provides comprehensive products and services to improve animal health and food-animal production in more than 70 countries around the world.

History[edit | edit source]

Elanco was established as a division of Eli Lilly and Company in 1954. In 2018, Elanco became a fully independent company following its Initial Public Offering (IPO). The company's mission is to innovate, collaborate and lead with a strong commitment to improving the health of animals, benefiting their owners, and contributing to the wellbeing of communities.

Products and Services[edit | edit source]

Elanco's portfolio of products and services are designed to prevent and treat disease in both companion animals and food animals. This includes a range of antibiotics, vaccines, parasiticides, and nutritional supplements. Elanco also provides a suite of services to support veterinarians, farmers, and pet owners, including diagnostic tests, training, and consulting.

Research and Development[edit | edit source]

Elanco's research and development (R&D) efforts are focused on finding innovative solutions to some of the world's most pressing animal health challenges. The company invests heavily in R&D, with a focus on developing new products, improving existing products, and exploring new technologies.

Corporate Responsibility[edit | edit source]

Elanco is committed to corporate responsibility, with a focus on improving animal health, ensuring food safety, reducing environmental impact, and contributing to communities. The company's corporate responsibility efforts are guided by its Healthy Purpose™ 2030 strategy, which sets ambitious goals for improving the health of people, animals, and the planet.